About: Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial Goto Sponge Distinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 September 1994

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована у вересні 1994 (uk) article scientifique publié en 1994 (fr) im September 1994 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en setiembre de 1994 (ast) scientific article published on 01 September 1994 (en)
publication date	wds:Q72182720-EBAC0CEB-2548-4AE8-B6A7-311EEBEE3CB2
publication date	1994-09-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q72182720-00DC82F0-3673-41A4-AF8A-BAB07E359DB4
language of work or name	English
author name string	wds:Q72182720-091604A8-885E-4D17-A1FA-E18936083652 wds:Q72182720-0B329946-2106-4478-80EF-C0D09F35E64E wds:Q72182720-1015EADE-A4FB-4276-ADD5-A1CF25C74D74 wds:Q72182720-3B6B5A87-15A0-47E0-8653-213941371772 wds:Q72182720-4C287CCA-4353-46A4-BA59-3005A61A6813 wds:Q72182720-5E368F58-49F0-4875-82CF-590635EAFE81 wds:Q72182720-60EAF824-55EB-4270-82C6-EB9DE8E49B80 wds:Q72182720-86F63595-3945-45E9-AFE5-6FBB2229DAC6 wds:Q72182720-8E10F85E-FEC9-4A21-94AD-0425777C5DA2 wds:Q72182720-A3F7E29D-AF2D-4B61-B7CC-27514C900265
author name string	J Paul G C Wishart D J Kerr D Bissett M A Macham R C Leonard M Soukop T Habeshaw D Jodrell A Harnett
rdfs:label	Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial (en) Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial (nl)
skos:prefLabel	Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial (en) Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial (nl)
name	Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial (en) Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial (nl)
title	wds:Q72182720-1F243C12-ACA4-4D48-B448-C494B454300D
title	Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial (en)
page(s)	wds:Q72182720-54C21020-579F-4610-9E15-084F14B0E6D0
page(s)	1771-1777
instance of	wds:Q72182720-C39864A2-633F-4BBB-BCBC-3D9578C8ACFD
instance of	scholarly article
uses	wds:Q72182720-6A45D0F4-B9F0-4BA4-B06B-FAC5B6F96D87
uses	randomized experiment
main subject	wds:Q72182720-88725C32-F206-4CCB-9C48-38509E8E3046
main subject	placebo
PubMed ID	wds:Q72182720-CBFEE1C8-FC43-44B2-9BA9-26BDD001A080
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/8083699
PubMed ID	8083699
published in	wds:Q72182720-0A0CA01D-7724-424A-B77C-A5A099E7CCD4
published in	Journal of Clinical Oncology
issue	wds:Q72182720-1D68C9D2-C949-4836-B620-F1767428B5B3
volume	wds:Q72182720-036AA925-D4B5-406E-938D-F2F152680BAA
issue	9
volume	12
DOI	wds:Q72182720-EF1489CF-439C-422A-A600-6168832171E5
DOI	http://dx.doi.org/10.1200/JCO.1994.12.9.1771
DOI	10.1200/JCO.1994.12.9.1771
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q72182720
is cites work of	Targeting tumor microenvironment with PEG-based amphiphilic nanoparticles to overcome chemoresistance Targeting multidrug resistance in cancer The Role of ABC Transporters in Clinical Practice Combination chemotherapy with cyclophosphamide, vincristine, adriamycin, and dexamethasone (CVAD) plus oral quinine and verapamil in patients with advanced breast cancer Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP. Phase I study of cinchonine, a multidrug resistance reversing agent, combined with the CHVP regimen in relapsed and refractory lymphoproliferative syndromes. Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma Drug penetration in solid tumours Evolutionary approaches to prolong progression-free survival in breast cancer Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs Tumour stem cells and drug resistance Historical, current and future aspects of osteosarcoma treatment Results of a phase III, double-blind, placebo-controlled trial of megestrol acetate modulation of P-glycoprotein-mediated drug resistance in the first-line management of small-cell lung carcinoma Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies. 99mTc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein Effects of adjuvant chemotherapy on the natural history and likelihood of therapeutic efficacy in advanced breast cancer patients: a critical literature review Epirubicin chemotherapy and advanced breast cancer after adjuvant CMF chemotherapy Development of multidrug-resistance convertors: sense or nonsense? Future perspectives for the development of P-glycoprotein modulators Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein Priming cancer cells for drug resistance: role of the fibroblast niche Clinical studies with modulators of multidrug resistance. Epirubicin. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of breast cancer The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments Epirubicin: a review of its efficacy as adjuvant therapy and in the treatment of metastatic disease in breast cancer Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer
is cites work of	wds:Q33585752-3CB694DD-9F4E-4C1B-8021-908612AFA8D1 wds:Q41388354-BDF77EAF-98F1-4D03-B79A-9BADF3FDC00D wds:Q35884806-35A3138C-22AF-4F10-A340-79631DC90D7A wds:Q34060806-3593E43B-81FC-454C-A3C4-1481E40BA806 wds:Q73356015-5994D8A4-B2A9-4C40-8164-35CB6821467E wds:Q33795872-6F965177-7834-4F5D-A72A-40A4CF01D538 wds:Q38232067-44E00E43-62EA-46C9-BEB7-987CA71658A1 wds:Q37378180-3D93A254-4B88-41DD-8B34-A2A44D180428 wds:Q41064272-D9FAF409-1D72-4F9A-A4D1-A2897F5B673E wds:Q29616803-DF21A563-13C7-497D-B207-E3A28685F828 wds:Q29614404-383138EC-3C26-4E3B-A53A-02912A2EEE84 wds:Q36291680-A198DA8A-2F05-4F9F-BA44-D2C516712905 wds:Q36476358-54F2DC4F-FDF0-45E0-8FD1-8FFE825BCF34

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software